TuHURA Biosciences (NASDAQ:HURA) Rating Increased to Hold at Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Several other analysts have also recently weighed in on HURA. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Wednesday, October 8th. Maxim Group dropped their price target on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $10.33.

TuHURA Biosciences Price Performance

Shares of HURA stock opened at $1.94 on Friday. The company has a fifty day moving average price of $2.27 and a two-hundred day moving average price of $2.53. TuHURA Biosciences has a one year low of $1.56 and a one year high of $6.90. The stock has a market cap of $99.44 million, a P/E ratio of -3.88 and a beta of -0.03.

TuHURA Biosciences (NASDAQ:HURA) last posted its earnings results on Friday, November 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01.

Institutional Trading of TuHURA Biosciences

A number of hedge funds have recently made changes to their positions in the company. Bank of America Corp DE bought a new stake in TuHURA Biosciences during the 4th quarter worth approximately $59,000. Jane Street Group LLC acquired a new position in shares of TuHURA Biosciences during the first quarter worth $69,000. Invst LLC bought a new stake in shares of TuHURA Biosciences in the first quarter worth $61,000. Suncoast Equity Management increased its holdings in TuHURA Biosciences by 4.4% in the second quarter. Suncoast Equity Management now owns 104,409 shares of the company’s stock valued at $233,000 after purchasing an additional 4,412 shares during the period. Finally, Geode Capital Management LLC raised its position in TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after purchasing an additional 307,260 shares during the last quarter. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.